What is Exelixis's market cap?

Exelixis (EXEL) has a market capitalization of $14.0B and trades on NASDAQ.

What is Exelixis's revenue and profitability?

Exelixis generated $2.4B in trailing twelve-month revenue with net income of $833.4M, representing a net margin of 35.1%. Gross margin stands at 96.4%, with free cash flow of $917.7M. These figures are based on the Q2 2026 filing.

Who are Exelixis's competitors?

Exelixis's key competitors include Eli Lilly, Pfizer, Karyopharm Therapeutics Inc., and others. These companies compete in similar markets and product categories.

Who does Exelixis partner with?

Exelixis's notable partners include Ipsen, Takeda Pharmaceutical Company, Bristol-Myers Squibb, and others.

Where is Exelixis headquartered?

Exelixis is headquartered in United States of America and employs approximately 1,310 people. It has been publicly traded since 2000.

Exelixis

EXEL

Exelixis Inc is a fully integrated oncology company focused on the discovery, development, and commercialization of next-generation cancer treatments.

Market cap

$14.03B+41.4%

Revenue$2.4B+3.3%

Net income$833.4M+29.5%

Free cash flow$917.7M+11.8%

EPS (diluted)$3.01+36.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$610.8MBeat by $3.3M EPS$0.87Beat by $0.12

Read the full report

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$636.4M

EPS estimate$0.86

Financials

Q1 2026

Income statement

See full

Revenue$610.8M+10.0%

Gross profit$590.9M+10.2%

Operating income$251.3M+34.5%

Net income$210.5M+31.9%

EPS (diluted)$0.79+43.6%

Balance sheet

See full

Cash & equivalents$226.2M+23.1%

Total debt$169.5M-9.4%

Total equity$1.9B-9.2%

Total assets$2.6B-8.6%

Cash flow

See full

Operating cash flow$251.8M+19.1%

CapEx$1.5M-48.9%

Free cash flow$250.3M+20.1%

Valuation & ratios

Valuation

See full

Market cap$14.03B+41.4%

Enterprise value$13.97B+15.4%

P/E16.8×-2.0×

P/S5.9×+0.6×

Profitability

See full

Gross margin96.4%-0.3pp

Operating margin39.4%+6.3pp

Net margin35.1%+7.1pp

FCF margin38.6%+2.9pp

Returns & leverage

See full

Return on equity41%+10.8pp

Debt / equity0.1×0.0×

Current ratio3.3×-0.2×

Segments

By product

See full

Gross product revenues$795.4M+10.2%

License revenues$56.9M+34.1%

Collaboration$55.8M+32.4%

Collaboration services revenues-$4.0M-211%

Discounts and allowances-$240.4M-15.3%

By segment

See full

Reportable Segment$610.8M+10.0%

Competitors

By market cap

Eli Lilly$1.07T+47.2%

Pfizer$140.61B+1.7%

Exelixis$14.0B+15.9%

Immunome$2.6B+171%

Verastem$534.3M+61.5%

Puma Biotechnology$406.7M+145%

Karyopharm Therapeutics$160.7M+326%

Exicure$11.2M-75.5%

By revenue growth

Eli Lilly+47.4%

Exelixis+3.3%

Pfizer+1.4%

Immunome-63.3%

By net margin

Exelixis35.08%+7.1pp

Eli Lilly34.99%+12.3pp

Pfizer15.65%+6.3pp

Immunome-5,593.85%-3,719pp

Profile

Exelixis Inc is a fully integrated oncology company focused on the discovery, development, and commercialization of next-generation cancer treatments. The company leverages its expertise in small molecules and biotherapeutics, such as antibody-drug conjugates, to address high unmet medical needs in various solid tumors. Its core value proposition is built on its flagship tyrosine kinase inhibitor franchise and a growing pipeline of clinically differentiated assets.

Competitive position

A leading oncology-focused biotechnology company with a dominant position in the renal cell carcinoma market through its cabozantinib franchise.

GeographiesUnited States, European Economic Area, Japan, Canada

Customer segmentsHealthcare providers, Pharmaceutical distributors, Global biopharmaceutical companies

Business modelR&D-driven drug development, Direct product sales, Licensing and royalties

SuppliersContract manufacturing organizations, Raw material suppliers, Third-party logistics providers, Clinical research organizations

CustomersWholesale drug distributors, Specialty pharmacies, Hospitals and cancer centers, International commercialization partners

CountryUnited States of America

Listed2000

Employees1.3K

CEOMichael Morrissey

SectorHealthcare

IndustryBiotechnology

Websiteexelixis.com

FilingsSEC EDGAR

Ask your AI about Exelixis.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Exelixis's market cap?: Exelixis (EXEL) has a market capitalization of $14.0B and trades on NASDAQ.
What is Exelixis's revenue and profitability?: Exelixis generated $2.4B in trailing twelve-month revenue with net income of $833.4M, representing a net margin of 35.1%. Gross margin stands at 96.4%, with free cash flow of $917.7M. These figures are based on the Q2 2026 filing.
Who are Exelixis's competitors?: Exelixis's key competitors include Eli Lilly, Pfizer, Karyopharm Therapeutics Inc., and others. These companies compete in similar markets and product categories.
Who does Exelixis partner with?: Exelixis's notable partners include Ipsen, Takeda Pharmaceutical Company, Bristol-Myers Squibb, and others.
Where is Exelixis headquartered?: Exelixis is headquartered in United States of America and employs approximately 1,310 people. It has been publicly traded since 2000.